Home - The Science Behind

Helping clients to de-risk future pipeline decisions and capture growth and opportunities to build differentiated capabilities.

About Us

The Science Behind Limited specialises in delivering cutting-edge neuroscience technologies and capabilities tailored for early-phase clinical trials focused on neurodegenerative diseases and central nervous system disorders. Our team develops multimodal solutions, integrated into complex clinical trial designs to cost-effectively leverage central nervous system measures, and provide unparalleled objective insights into physiological responses to drug effects.

Our Services

As a trial or research group, you can access our services on a study-by-study basis without the need to make significant capital investment in technology and expertise. Giving you the freedom to enhance your service offer or build elements into your study as and when you need to.

Clinical Research Services

The Science Behind is uniquely able to offer services to support Phase I clinical trials during volunteer screening and trial to facilitate the reduction of overall development costs,…

Pharmaco-EEG

Quantifying Drug Effects on Brain Activity What We Offer Advantages of Pharmaco-EEG Frequently Asked Questions Additional Resources Neural synchronisation deficits linked to cortical hyper-excitability and auditory hypersensitivity in…

Pharmaco-TMS

A pharmacodynamic readout of cortical activity Neurotransmitters Commonly Targeted by TMS Drug Example Drug Effect on MEP TMS-induced PD Effect D-Cycloserine Enhanced facilitatory effect of MEP Increased glutamatergic…

Cognitive & Physiological

The Science Behind have the capability to tailor specific cognitive or physiological assessments within our neurostimulation and neuroimaging services for each clinical trial. This customisation demonstrates our deep…

Quantitative Sensory Testing

Quantitative Sensory Testing (QST) is a method used to objectively measure sensory perception, including pain, in response to various stimuli (e.g., heat, cold, pressure). Incorporating QST into your…

15th June 2023

Enhancing Drug Abuse Potential Assessments: The Role of Cognitive Test Batteries and Neuroimaging Techniques in Human Clinical Trials

Drug abuse liability studies are vital for assessing the potential of a drug to be abused. While preclinical trials provide important insights, it is equally important to evaluate…

11th April 2023

A Promising New Drug for Treating Cognitive Decline in Schizophrenia

The Science Behind is playing a crucial role in the neurophysiological screening and monitoring of a phase I clinical trial for a new drug, MDI-26478, developed by Cardiff University’s…

28th February 2023

The Science Behind Supports Rare Disease Day

Rare Disease Day is an important annual observance that raises awareness about rare diseases and their impact on patients’ lives. First established in 2008 by EURODIS, it has…

7th February 2023

Recognised as the Best in Early Phase Neuroscience Clinical Trials.

Our Company Wins European Enterprise Award. Exciting news! Our company has been awarded the Best Early Phase Neuroscience Clinical Trials CRO at the European Enterprise Awards! This recognition…

17th January 2023

Revolutionising Drug Development: The Power of TMS-EEG in First in Human Clinical Trials

Pharmaceutical companies are constantly searching for new and innovative ways to test the safety and efficacy of their drugs, and one promising method, TMS-EEG, is the use of transcranial magnetic stimulation…

4th January 2022

Webinar: Embedding neuroscience for target engagement in FiH clinical trials

The Science Behind and contract research organisation Simbec-Orion jointly hosted a free webinar on Wednesday 19th January 2022 on Embedding Neuroscience Techniques to Measure Target Engagement in First-In-Human (FIH)…

About Us